Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$24.62 USD
-0.04 (-0.16%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $24.65 +0.03 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Myriad Genetics, Inc. [MYGN]
Reports for Purchase
Showing records 181 - 200 ( 243 total )
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Terminating Coverage Due to Analyst Departure.
Provider: COLLIERS SECURITIES
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: CMS Releases Preliminary Payment Methodology Continued Uncertainty for BRACAnalysis Reimbursement Until at Least November, Maintain NEUTRAL
Provider: COLLIERS SECURITIES
Analyst: HUSAIN J
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: CMS Releases Preliminary Payment Methodology Continued Uncertainty for BRACAnalysis Reimbursement Until at Least November, Maintain NEUTRAL
Provider: COLLIERS SECURITIES
Analyst: HUSAIN J